



### Manage your dispensary workflow with ease

Fri 5th March 2021

# PSA PI scheme backed by members

**MOVES** by the Pharmaceutical Society of Australia (PSA) to launch a professional indemnity (PI) insurance product are a response to members' desires for an alternative to current offerings, CEO, Mark Kinsela, says.

Speaking to *Pharmacy Daily*, Kinsela said the PSA Board had set a focus on building its member value proposition by developing products to help and support pharmacists throughout their careers.

He noted that responses to member surveys had indicated there was a demand for the PSA to provide PI insurance, which was reinforced with the first sale of the product coming within 20 minutes of its launch last weekend.

Kinsela said the PSA had identified international insurance broker, BMS, to facilitate the new PI scheme, in part due to its history of working with peak professional bodies and its ability to provide cover for the



expanding services pharmacists are set to provide, including the administration of COVID-19 immunisations.

The new policy will be available exclusively to PSA members on an opt-in basis - not as an opt-out as previously reported (*PD* 04 Mar). With cost identified as a

"big factor" for pharmacists particularly those in the early stages of their careers the PSA PI policy will be available from \$170.50 to \$182.60 per year.

While the scheme is set to put the PSA in competition with the profession's leading indemnity insurer, Pharmaceutical Defence Limited (PDL), Kinsela told **Pharmacy Daily** that the Society would continue to "welcome and work with PDL".

Macrogol

PHARMACY MEDICINE REEP OUT OF REACH OF CHILDREN

Ibuprofen

**Plus Paracetamol** 

Cough Relief

APOHEALTH) With Electrolytes

## Today's issue of *PD*

Medview eRx:

*Pharmacy Daily* today features three pages of news.

### Monash honours Fred IT CEO

**FRED** IT CEO and cofounder, Paul Naismith, has been honoured by his alma mater, Monash University, for his success in developing pharmacy IT infrastructure.

Naismith was named as one of 11 recipients of the university's 2020 Distinguished Alumi Awards.

Monash noted that under Naismith's leadership Fred IT has launched innovative services including, eRx Script Exchange, MedView and has introduced real-time prescription monitoring systems to save lives and reduce the accidental misuse of prescription medicines.

### Quality over the counter medicines you can trust



The APOHEALTH range has been developed to offer your customers quality and affordable over-thecounter medicines that you can rely on. With over 80 products in our range, APOHEALTH covers key categories including:

Spray Forte

- HAYFEVER & ALLERGY
- COUGH, COLD & FLU
- ANALGESICS
- DIGESTIVE HEALTH
- ANTI-FUNGAL
- FEMININE CARE
- EYE & EAR CARE
- SKIN CARE
- EMERGENCY CONTRACEPTION
- VITAMIN SUPPLEMENTS

#### Available via major wholesalers

www.apohealth.com.au

These medicines may not be right for you. Read the label before purchase. Follow the directions for use. If symptoms persist, talk to your health professional.

t 1300 799 220

APOHEALTH

PHARMACY MEDICINE REEP OUT OF REACH OF ONE DREAD

Cetirizine

layfever & Allergy Re

Anti-Fungal Cream



keep dreaming... Inspiration for your next escape

Fri 5th March 2021

#### New markets for Maxigesic IV

**AFT** Pharmaceuticals has signed an exclusive licensing agreement with Aguettant Essential Medicines to distribute Maxigesic IV in eight new European markets.

Under the deal Aguettant has rights to the medicine in Spain, Portugal, the Netherlands, Finland, Norway, Denmark, Sweden and Iceland, with sales of the medication due to commence in these territories next year.

AFT Managing Director, Dr Hartley Atkinson, said the agreement extends Maxigesic IV's footprint across Europe, noting that in Spain alone more than 2.5 million surgeries are performed annually, while a further 1.1 million are performed in the nordic nations, with Maxigesic IV offering a non-opiate alternative for pain relief. **COVERING** pharmacists' dispensing fees for opioid substitution therapy (OST) could be key to removing barriers to accessing treatment for patients in Victoria, State MP, Dr Tim Read, believes.

Speaking in the Victorian Legislative Assembly earlier this week, the Greens MP, noted that while some OST medications have been listed on the Pharmaceutical Benefits Scheme (PBS), the dispensing fees have not been covered, leaving patients with outof-pocket expenses.

"They [dispensing fees] are typically \$30-\$35 a week, and that fee, I am told by pharmacists, has not increased in 30 years," he said.

"When you consider the interaction that they have with the patient, the consumables and the time spent, that is not a lot for them to ask.

"But patients often do not have the money and do not pay. "It sets up a tension between the pharmacist and the patient, and patients too often fall off the wagon.

Victoria needs to address OST fees

"I had one patient die almost certainly as a consequence of not being able to pay for her methadone.

"I think we have a system that puts up significant barriers to people receiving the best treatment to stop their heroin or other opioid use, and methadone, naloxone and buprenorphine are regarded as the best treatments for heroin addiction.

"There are more than 50,000 people using this kind of treatment in Australia, and every state other than Victoria provides some form of subsidy or access.

"So I think this is a real challenge for the Victorian Government and one that I recommend the government accept.

"I think that with these dispensing costs, when compared to the costs



Travel & Cruis

of, say, the hospital admission of the patient that I mentioned—who fell off the wagon, used heroin and got a heart valve infection and spent months in hospital—a \$30-to-\$35-a-week dispensing fee pales into insignificance."

Read also flagged concerns over the shortage of doctors prescribing OST in Victoria, noting it was a role that nurse prescribers could fill in the future.



Always read the label. Follow the directions for use. Vitamin and mineral supplements should not replace a balanced diet. Do not exceed the stated dose except on medical advice. If you have had a baby with a neural tube defect/spina bifida, seek specific medical advice.



Dispensary

Corner

*keep dreaming...* Travel inspiration for your next holiday



Fri 5th March 2021

## WA pharmacy reform on the table

**PRINCE** Harry and his wife Meghan Markle have become embroiled in a curious trademark lawsuit, arguing about the name of a deodorant sold in the Philippines.

The World Trademark Review website notes a Jul 2020 application from a businessman named Victor Martin Soriano for a new antiperspirant called "Archewell Harvatera".

A formal opposition notice to the name has been lodged with the Intellectual Property of the Philippines by Cobblestone Lane LLC, the former royal couple's private company.

Archewell happens to be the name of the Duke and Duchess' private foundation which aims to "unleash the power of compassion to drive systemic cultural change".

But in the Philippines the term is apparently also being already used for branding a range of products including engagement rings and cosmetics.



**POLITICIANS** from Western Australia's four main parties are committed to moving forward with key reforms of the community pharmacy sector after next week's State election.

Pharmacy Guild of Australia WA Branch President, Andrew Ngeow, welcomed written statements of support for the Guild's 2021 General Election Platform, from WA Labor, WA Liberal Party, the Nationals WA and the Greens WA.

"We were very pleased to have received such a strong level of commitment to community pharmacy," Ngeow said.

The Platform urged the incoming Government to utilise community pharmacy within the State's primary health network to improve patient outcomes.

"As a key part of the primary healthcare sector, the WA

### SAS update

HEALTH professionals are being invited to attend one of two webinars walking through changes to the Special Access Scheme (SAS) and Authorised Prescriber Online System.

The Therapeutic Goods Administration noted that the SAS Category B online form has been updated to reflect legislative changes. CLICK HERE to register now. Branch thought it of the utmost importance to develop and advocate on a set of reforms which are effectively a blueprint for community pharmacy to deliver improved and more cost-effective health outcomes for all Western Australians," Ngeow said.

"There can be no doubt that the COVID-19 pandemic has highlighted the urgent need for better utilisation of the training, expertise and experience within community pharmacy.

"I believe that the strong commitment received from the major political parties in Western Australia is recognition of that."

Having secured the support of the major parties, Ngeow said that following the election the Guild will commence working with the State Government to address the Platform's immediate



priorities including expanding the pharmacy immunisation program to include COVID-19, the National Immunisation Program and travel vaccines, to implement continued dispensings on a permanent basis, to ensure greater inclusion of the community pharmacy sector in emergency and disaster planning, and to push for a review of the Commercial Tenancy (Retail Shops) Agreement 1985, to address the current imbalance in landlord/ tenant relations.



dermaltherapy.com.au

Pharmacy Daily

www.pharmacydaily.com.au Pharmacy Daily is part of the Business Publishing Group family

of publications. Pharmacy Daily is Australia's

**Pharmacy Daily** is Australia's favourite pharmacy industry publication.

EDITORIAL Editor in Chief and Publisher – Bruce Piper Editor – Nicholas O'Donoghue Contributors – Adam Bishop, Myles Stedman info@pharmacydaily.com.au ADVERTISING AND MARKETING Sean Harrigan, Hoda Alzubaidi advertising@pharmacydaily.com.au

BUSINESS MANAGER Jenny Piper accounts@pharmacydaily.com.au Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia PO Box 1010 Epping NSW 1710 Australia Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at www.pharmacydaily.com.au

Travel Daily

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

**Pharmacy Daily** 

e info@pharmacydaily.com.au

t 1300 799 220

w www.pharmacydaily.com.au

page 3